In conclusion, correction of anemia (Hb levels 12.5–13.5 mg/dL) with an ESA showing a longer half-life prevents the progression of chronic allograft nephropathy in KTx recipients, as long as BP is appropriately controlled. The gene discussed is GSTM1; the disease is anemia.